Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Aug;203(2):112-9.
doi: 10.1192/bjp.bp.112.124784. Epub 2013 Jul 11.

Stimulant Treatment for Attention-Deficit Hyperactivity Disorder and Risk of Developing Substance Use Disorder

Affiliations

Stimulant Treatment for Attention-Deficit Hyperactivity Disorder and Risk of Developing Substance Use Disorder

Annabeth P Groenman et al. Br J Psychiatry. .

Erratum in

  • Br J Psychiatry. 2014 Jun;204(6):494

Abstract

Background: Attention-deficit hyperactivity disorder (ADHD) is linked to increased risk for substance use disorders and nicotine dependence.

Aims: To examine the effects of stimulant treatment on subsequent risk for substance use disorder and nicotine dependence in a prospective longitudinal ADHD case-control study.

Method: At baseline we assessed ADHD, conduct disorder and oppositional defiant disorder. Substance use disorders, nicotine dependence and stimulant treatment were assessed retrospectively after a mean follow-up of 4.4 years, at a mean age of 16.4 years.

Results: Stimulant treatment of ADHD was linked to a reduced risk for substance use disorders compared with no stimulant treatment, even after controlling for conduct disorder and oppositional defiant disorder (hazard ratio (HR) = 1.91, 95% CI 1.10-3.36), but not to nicotine dependence (HR = 1.12, 95% CI 0.45-2.96). Within the stimulant-treated group, a protective effect of age at first stimulant use on substance use disorder development was found, which diminished with age, and seemed to reverse around the age of 18.

Conclusions: Stimulant treatment appears to lower the risk of developing substance use disorders and does not have an impact on the development of nicotine dependence in adolescents with ADHD.

Comment in

  • Stimulant treatment for ADHD.
    Verma R, Apala, Kumari S, Dhiman V. Verma R, et al. Br J Psychiatry. 2014 Jun;204(6):490. doi: 10.1192/bjp.204.6.490a. Br J Psychiatry. 2014. PMID: 25029692 No abstract available.
  • Authors' reply.
    Groenman AP, Oosterlaan J, Rommelse NN, Franke B, Greven CU, Hoekstra PJ, Hartman CA, Luman M, Roeyers H, Oades RD, Sergeant JA, Buitelaar JK, Faraone SV. Groenman AP, et al. Br J Psychiatry. 2014 Jun;204(6):490-1. doi: 10.1192/bjp.204.6.490b. Br J Psychiatry. 2014. PMID: 25029693 No abstract available.

Similar articles

See all similar articles

Cited by 19 articles

See all "Cited by" articles

Publication types

MeSH terms

Substances

Feedback